Want to see TSE:LEXT full AI Analyst Report?
Top Page
Lexston Life Sciences Corp.
(LEXT)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.08
▼(-18.00% Downside)
Action:Reiterated
Date:07/01/26
The score is primarily weighed down by weak financial performance (zero recent revenue, ongoing losses, and continued cash burn). Valuation is also not supportive due to negative earnings (negative P/E) and no dividend yield data, while technicals cannot be assessed due to missing indicator inputs.
Positive Factors
Low Leverage
Zero reported debt is a durable structural advantage: it reduces fixed financing obligations and bankruptcy risk, giving management financial flexibility to raise equity or deploy limited cash for operations or strategic options without servicing interest, important given ongoing losses.
Negative Factors
Zero Recent Revenue
Sustained zero revenue undermines the firm's ability to develop a self-sustaining business model. Without recurring sales or commodity production, management must rely on external capital, limiting long-term profitability prospects and making the firm dependent on financing cycles rather than operational cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Zero reported debt is a durable structural advantage: it reduces fixed financing obligations and bankruptcy risk, giving management financial flexibility to raise equity or deploy limited cash for operations or strategic options without servicing interest, important given ongoing losses.
Read all positive factors
Lexston Life Sciences Corp. (LEXT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.13M
Dividend YieldN/A
Average Volume (3M)40.70K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue GrowthN/A
EPS Growth55.26%
CountryCA
EmployeesN/A
SectorBasic Materials
Sector Strength58
IndustryGold
Share Statistics
EPS (TTM)-0.14
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lexston Life Sciences Corp. Business Overview & Revenue Model
Company Description
Based in Vancouver, Canada, Lexston Life Sciences Corp. operates as a biotechnology firm. The company offers comprehensive cannabis testing and research services across Canada, in addition to analytical evaluations for cannabis, pathogens, and tox...
Lexston Life Sciences Corp. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Aug 2025 | Aug 2024 | May 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 361.01K | 149.11K |
| Gross Profit | 0.00 | 0.00 | -26.39K | -29.80K | 241.49K | 60.10K |
| EBITDA | -1.45M | -1.54M | -648.32K | -841.73K | -2.29M | -479.82K |
| Net Income | -1.53M | -1.62M | -867.71K | -1.11M | -2.32M | -876.13K |
Balance Sheet | ||||||
| Total Assets | 1.16M | 279.49K | 750.95K | 814.30K | 952.80K | 1.10M |
| Cash, Cash Equivalents and Short-Term Investments | 278.52K | 2.32K | 390.40K | 511.00K | 590.49K | 949.17K |
| Total Debt | 8.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 130.55K | 208.82K | 39.87K | 11.21K | 79.09K | 38.81K |
| Stockholders Equity | 1.02M | 70.67K | 711.08K | 803.10K | 873.71K | 1.06M |
Cash Flow | ||||||
| Free Cash Flow | -1.02M | -1.19M | -723.16K | -987.74K | -1.40M | -608.63K |
| Operating Cash Flow | -1.02M | -1.19M | -523.18K | -987.74K | -1.40M | -483.16K |
| Investing Cash Flow | -58.63K | -10.00K | -199.99K | 0.00 | -109.97K | 812.32K |
| Financing Cash Flow | 1.30M | 814.66K | 602.57K | 908.24K | 1.15M | 620.01K |
Lexston Life Sciences Corp. Technical Analysis
Positive
0.10
Price Trends
0.06
Positive
0.07
Positive
0.12
Negative
Market Momentum
<0.01
Negative
56.50
Neutral
37.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LEXT, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.50 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:LEXT.
Lexston Life Sciences Corp. Peers Comparison
UnderperformOutperform
Sector (61)
TSE:LEXT
Lexston Life Sciences Corp.
0.09
-0.06
-43.33%
TSE:LSD.H
Lightspeed Discoveries
0.07
0.04
133.33%
TSE:LCR
NeonMind Biosciences Inc
0.02
-0.04
-66.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.